Centiva Capital’s Akebia Therapeutics AKBA Stock Holding History

Centiva Capital’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13,638	Closed	-$5K	–	1465
2022 Q2	$5K	Buy	+13,638	New	+$5.72K	﹤0.01%	1578

Other funds holding AKBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Centiva Capital's AKBA Position: Q3 2022 in Review

Centiva Capital sold out of Akebia Therapeutics (AKBA) in Q3 2022, closing a stake of 13,638 shares — an estimated $5K sold.

Centiva Capital first reported a position in AKBA in Q2 2022 and held it in 1 quarter. The position peaked at $5K in Q2 2022. 90 funds tracked by Wall St. Rank hold AKBA as of Q3 2022.

Centiva Capital reported no remaining Akebia Therapeutics position as of Q3 2022 after selling out during the quarter.
Centiva Capital sold 13,638 Akebia Therapeutics shares in Q3 2022, an estimated $5K.
Centiva Capital first reported a position in Akebia Therapeutics in Q2 2022 and held it in 1 quarter.
Centiva Capital's Akebia Therapeutics position peaked at $5K in Q2 2022.
90 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2022.

Based on Centiva Capital's 13F filing for Q3 2022, filed 14 Nov 2022.